Business Context and Reporting Period
This Form 8-K is a current report filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on December 27, 2012. The registrant is a Delaware corporation headquartered in San Diego, California, focused on oncology research and clinical testing services.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a specific corporate event rather than a financial statement.
Material Changes
On December 27, 2012, the Company granted a non-exclusive license to Duke University and Duke University Health Systems. This license permits the incorporation of nucleophosmin protein (NPM1) into research and clinical testing services for acute myelogenous leukemia.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of risks and contingencies. The disclosure is made pursuant to Regulation FD (Item 7.01) and includes a press release as Exhibit 99.1. The information is furnished but not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the terms and financial implications of the non-exclusive license granted to Duke University.
- Confirm the specific scope of the NPM1 protein usage in acute myelogenous leukemia testing.
- Review the full text of the press release attached as Exhibit 99.1 for additional details.
- Note that this filing does not contain updated financial performance data.